Literature DB >> 25868013

Expanding the evidence base supporting shorter treatment durations for multidrug-resistant tuberculosis.

Eric Nuermberger1, Wing-Wai Yew2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25868013     DOI： 10.5588/ijtld.15.0110

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  3 in total

1.  Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Authors:  Rokeya Tasneen; Fabrice Betoudji; Sandeep Tyagi; Si-Yang Li; Kathy Williams; Paul J Converse; Véronique Dartois; Tian Yang; Carl M Mendel; Khisimuzi E Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

2.  Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.

Authors:  Si-Yang Li; Rokeya Tasneen; Sandeep Tyagi; Heena Soni; Paul J Converse; Khisimuzi Mdluli; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.

Authors:  Derek J Sloan; Joseph M Lewis
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.